Maiko Shimomura

Maiko Shimomura

Auto-generated profile, based on publicly available information

Maiko Shimomura

Department of Pediatrics Hiroshima University Hospital Hiroshima Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2014 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
SOSeigo Okada
Seigo Okada
SHS Hasegawa
S Hasegawa
YSY Suzuki
Y Suzuki
TMT Matsubara
T Matsubara
MSM Shimomura
M Shimomura
SOS Ohga
S Ohga
To establish the optimal inflammation control of Kawasaki disease (KD), we investigated the clinical and pathophysiological basis of pericardial effusion (PE) during the acute phase of KD. Clinical and laboratory features of Japanese KD children with PE (PE group: n = 9) and without PE (non-PE group: n = 89) were studied retrospectively by using the medical records. Serum levels of soluble tumour necrosis factor receptor 1 (sTNFR1), interleukin 6 (IL-6), and vascular endothelial growth factor (VEGF) were assessed by enzyme-linked immunosorbent assays (ELISAs). PE group patients had coronary artery lesions (CALs) more frequently than non-PE group patients during the acute phase of KD (33% vs. 5.6%, p = 0.024). PE patients also showed lower levels of haemoglobin (p < 0.01) and serum albumin (p < 0.01) and higher platelet counts (p = 0.013) than non-PE patients. The proportion of neurological symptoms, but not other manifestations, in the PE group was higher than in the non-PE group (p = 0.022). All patients survived free from coronary artery aneurisms. Serum levels of sTNFR1, but not the other cytokines, in the PE group were higher than those in the non-PE group (p < 0.001). The sTNFR1 levels correlated positively with C-reactive protein (CRP) (r = 0.30, p = 0.019) or total bilirubin (r = 0.40, p < 0.01) levels. Acute PE in KD patients indicated the severity of TNF-mediated vascular inflammation and concurrent CALs. According to the progression, these patients might need more targeted therapy of anti-inflammation for a better coronary outcome.

1 January 2019 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
SOSeigo Okada
Seigo Okada
YIYuichi Ishikawa
Yuichi Ishikawa
MSMaiko Shimomura
Maiko Shimomura
SSShinpei Sunagawa
Shinpei Sunagawa
RHReiji Hirano
Reiji Hirano
TMTakashi Maki
Takashi Maki
Okada S, et al. Yonsei Med J. 2019 Mar;60(3):312-314. https://doi.org/10.3349/ymj.2019.60.3.312

6 March 2026 in Blood
Verified
Journal Article
Closed access
PDF file
KMKaito Mimura
Kaito Mimura
AKAkira Kaino
Akira Kaino
YOYotaro Ochi
Yotaro Ochi
YCYu-Hsuan Chang
Yu-Hsuan Chang
MSMasafumi Seki
Masafumi Seki
KYKenichi Yoshida
Kenichi Yoshida
The molecular classification of T-cell acute lymphoblastic leukemia (T-ALL) remains incomplete, limiting risk stratification and the development of targeted therapies. Enhancer hijacking is a critical oncogenic mechanism that deregulates proto-oncogenes by repositioning cis-regulatory regions via structural variants. Here, we performed an integrated analysis of pediatric and adult T-ALL and mixed phenotype acute leukemias (MPALs), using whole-genome and whole-transcriptome sequencing. This analysis identified a group of 14 patients with predominantly T-lineage neoplasms driven by a t(14;16)(q32;q24) translocation, harboring universal GATA3 mutations and CDKN2A/B deletions. Mechanistically, this translocation repositions the ThymoD locus downstream of BCL11B, causing monoallelic, ectopic overexpression of FENDRR and mesenchymal transcription factor genes FOXF1 and FOXC2, activating epithelial-mesenchymal transition (EMT) transcription signatures. Immunophenotypic and single-cell RNA-seq analyses revealed marked lineage ambiguity with myeloid and B-cell differentiation potentials specific to this subtype. Furthermore, functional analyses in CD34-positive cord blood cells demonstrated that FOXF1 overexpression promotes myeloid differentiation while suppressing T-cell differentiation, serving as a key factor for lineage specification. Clinically, this subtype was detected in 0.15-4.0% of T-ALL/MPAL cases depending on the cohort, showing a median age of 15 years and enrichment in adolescents and young adults (AYA). Importantly, patients with t(14;16)(q32;q24) have an extremely poor prognosis, showing a trend toward worse outcomes than high-risk groups such as KMT2A-rearranged early T-cell progenitor (ETP)-like, SPI1-rearranged, and LMO2 γδ-like T-ALLs. The unique molecular landscape and poor prognosis of patients with the t(14;16)(q32;q24) translocation underscore the need for the development of novel subtype-specific therapeutic approaches.

28 October 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MSMaiko Shimomura
Maiko Shimomura
KKKoji Kawaguchi
Koji Kawaguchi
SYShohei Yamamoto
Shohei Yamamoto
MKMichiko Kajiwara
Michiko Kajiwara
TKTakashi Koike
Takashi Koike
KUKatsutsugu Umeda
Katsutsugu Umeda

17 April 2025 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
MSMaiko Shimomura
Maiko Shimomura
YMYoko Mizoguchi
Yoko Mizoguchi
KKKyoko Kajihara
Kyoko Kajihara
FSFumiaki Sakura
Fumiaki Sakura
KNKosuke Noma
Kosuke Noma
SOSatoshi Okada
Satoshi Okada
Hemophilia is an inherited clotting disorder caused by a deficiency of factor VIII (FVIII) or factor IX (FIX), both of which are serine proteases in the intrinsic pathway of the coagulation cascade.[1] In recent years, patients with hemophilia have been able to lead normal active lives by maintaining appropriate factor levels through adequate replacement therapy, tailored to the intensity of their physical activity. However, individual differences in bleeding symptoms are frequently observed among patients with hemophilia, even when presenting at the same factor level of severity.[2] Some patients may experience hemorrhages despite having high clotting activity through receiving adequate replacement therapy.[3] Platelets play a critical role in primary hemostasis and thrombosis. Inherited platelet disorders (IPD) comprise a heterogeneous group of rare diseases caused by genetic defects that affect platelet formation and/or function. The clinical presentations in patients with IPD are highly variable, ranging from almost asymptomatic to those with severe bleeding symptoms even within families with the same genetic defect.[4] Thus, the phenotype of patients with IPD often becomes apparent only after external events such as surgery or trauma. Here we identified the coexistence of pathogenic variants in F9 and TBXA2R in siblings with hemophilia B who presented with treatment-resistant hemorrhages. TBXA2R encodes the thromboxane A2 receptor (TXA2R), and its genetic abnormalities are associated with an IPD. Initially, the siblings were exclusively diagnosed and treated for hemophilia B; however, despite maintaining adequate levels of factor activity, they experienced recurrent bleeding episodes. The occurrence of treatment-resistant bleeding raised suspicion of additional hemorrhagic complications. A thorough examination revealed abnormal platelet aggregation capacity, which ultimately led to the identification of a genetic abnormality in the TBXA2R gene through whole exome sequencing (WES). This report represents the first report of cases with combined variants in the F9 and TBXA2R genes. Case 1 is a 16-year-old boy who was diagnosed with severe hemophilia B (baseline FIX 10%) through regular replacement therapy, he started experiencing recurrent joint bleeds in his left ankle at the age of 9, ultimately developing a target joint. His annual joint bleeding rate (AJBR) reached three to four episodes per year. He had tried all types of rFIX products available in Japan and consistently maintained trough levels of FIX between 15 and 20%. Nevertheless, he continued to experience frequent bleeding in his left knee joint and right ankle. Additionally, he had prolonged postoperative bleeding following phimosis surgery and left ankle synovectomy, despite maintaining adequate factor activity. It became apparent that achieving hemostasis for this patient was challenging without maintaining factor activity close to 100% during bleeding episodes or postoperative care. Case 2 is a 12-year-old boy with severe hemophilia B (baseline FIX <1%), the younger brother of case 1. He began receiving weekly infusions of pdFIX at 9 months of age and switched to EHL-rFIX at 3 years of age. Despite maintaining a trough level of FIX between 10 and 20%, he experienced recurrent bleeding in his left hip joint. Additionally, around the age of 8, he began to easily develop muscle bleeds during physical activity. Furthermore, he frequently encountered challenges with hemostasis during tooth extractions. It is necessary to administer recombinant FIX (rFIX) immediately before each extraction at higher factor activity; otherwise, bleeding cannot be controlled. Due to the treatment-refractory hemorrhage observed in this sibling, we decided to investigate whether other bleeding disorders were present in addition to hemophilia B. In case 1, the activity levels of FVIII, factor XI, factor XII, and factor XIII were found to be normal. Additionally, the FIX antigen level was approximately 20% when the activity was at 5%, indicating that the patient had cross-reactive material (CRM) reduced hemophilia B. To determine whether primary hemostatic abnormalities were involved, we performed platelet light transmission aggregometry (LTA) using the Sysmex CN-6000. The assay revealed that the secondary aggregation wave in response to ADP (2 mM) was absent in both siblings ([Fig. 1A]). The TEG6s Platelet Mapping assay (Haemonetics Co., Braintree, MA) also showed that clot strength induced by ADP was reduced in both siblings compared with the control ([Fig. 1B 1–3]). Additionally, in case 1, reduced clot strength induced by arachidonic acid (AA) was also observed ([Fig. 1B 2]). Based on these results, we suspected the presence of a platelet function disorder in the siblings and subsequently performed WES on the siblings and their nonconsanguineous parents. All participants provided informed consent for genetic analysis (IRB #E2005–9109). WES revealed a hemizygous variant in F9 (c.128G > A, p.R43Q) in both siblings and the same heterozygous variant in F9 in their mother. Additionally, a heterozygous variant in the TBXA2R (c.179G > T, p.R60L) was identified in both siblings, which was also present in their mother ([Fig. 2A, B]). This variant has already been reported as a pathological variant.[5] [6] [7] [8] To further investigate platelet function in both siblings, we conducted a platelet function test using U46619 (9,11-Methanoepoxy Prostaglandin H2, Tocris Bioscience Cat#1932), a stable analog of TXA2 that serves as a potent TXA2 agonist. As a result, the siblings and their mother, who carried a heterozygous variant in the TBXA2R, demonstrated impaired aggregation in response to U46619 ([Fig. 3]). The clinical and genetic information on the siblings and the mother are summarized in [Table 1]. The mother, who is a carrier of hemophilia, had a FIX level of 22%, consistent with mild hemophilia B; however, she has not experienced...

16 October 2025 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
MKMasato Kojima
Masato Kojima
HKHiroki Kitagawa
Hiroki Kitagawa
KTKayoko Tadera
Kayoko Tadera
RTRyo Touge
Ryo Touge
SKSho Kurihara
Sho Kurihara
HOHiroki Ohge
Hiroki Ohge
Background: Digital polymerase chain reaction (dPCR) is a highly sensitive molecular method that allows rapid detection of bacterial DNA and resistance genes, requiring only a small blood volume. Although not a new technology, its application in pediatric patients with suspected catheter-related bloodstream infection (CRBSI) remains limited. Case presentation: A 16-year-old female, diagnosed with recurrent acute myelogenous leukemia, received re-induction chemotherapy through a peripherally inserted central venous catheter (PICC). The patient developed a fever, and the blood culture (BC) drawn from the PICC was positive for methicillin-resistant S. epidermidis, leading to suspicion of CRBSI. Several antibiotics were used, and the PICC was replaced. Eventually, the fever subsided, and the BC was negative after PICC removal. The levels of S. epidermidis-specific DNA sequences and mecA genes were correlated with the results of the BC and clinical course. Turnaround time was significantly shorter in dPCR (3.5 h) than in the BC (14–21 h); dPCR was performed using only 400 µL of blood. Conclusions: This case highlights the potential of dPCR as a complementary tool to conventional BCs in the management of pediatric CRBSI. dPCR may support rapid decision-making and monitoring of the treatment response, particularly when sample volumes are limited.